20 citations
,
August 1997 in “PubMed” Increased K+ permeability alone may not promote hair growth.
33 citations
,
May 1991 in “British Journal of Pharmacology” Cromakalim relaxes various blood vessels, while minoxidil sulphate is more selective; they likely act on different potassium channels.
119 citations
,
June 2005 in “Journal of Molecular and Cellular Cardiology” Potassium channel openers are effective in treating heart conditions, high blood pressure, pulmonary diseases, bladder issues, and hair loss, but more selective drugs are needed.
35 citations
,
March 2005 in “Journal of Investigative Dermatology” Potassium channel openers like minoxidil help hair grow by acting on hair follicles.
November 2010 in “Bradford Scholars (University of Bradford)” KATP channels are crucial for hair growth, and targeting them may lead to new hair loss treatments.
January 2022 in “Social Science Research Network” Potassium channel modulators mostly increase the activity of rat whisker mechanoreceptors.
34 citations
,
February 1992 in “Naunyn-schmiedebergs Archives of Pharmacology” Tedisamil and glibenclamide affect cromakalim and minoxidil sulphate differently in rat aorta.
January 2005 in “日本機械学會論文集. C編” Minoxidil sulfate and pinacidil promote hair growth likely by increasing blood flow, not by activating K channels.
37 citations
,
October 2009 in “Dermatology” Minoxidil stimulates hair growth by increasing hair thickness and prolonging growth phase.
13 citations
,
May 2011 in “Bioorganic & Medicinal Chemistry” Changing the 6-position on benzopyran molecules affects insulin release, with some compounds showing strong inhibitory effects.
Potassium channel openers like minoxidil boost hair growth.
144 citations
,
March 2013 in “Circulation Research” K_ATP channel gene mutations are linked to heart diseases, but more research is needed to understand the connection and treatment potential.
16 citations
,
July 1994 in “Journal of Dermatological Science” Minoxidil sulfate and pinacidil may promote hair growth through increased blood flow, not by activating potassium channels.
119 citations
,
October 1992 in “Fundamental & Clinical Pharmacology” Potassium channel openers could help treat cardiovascular diseases and asthma but require better targeting to specific tissues for effective use.
25 citations
,
December 2001 in “Expert Opinion on Pharmacotherapy” Potassium channel openers show promise for treating heart disease and other conditions, but more research is needed to fully understand their effects and safety.
6 citations
,
April 2014 in “European journal of medicinal chemistry” New compounds similar to cromakalim were less effective at inhibiting insulin release but improved in solubility and one acted as a calcium entry blocker, not a potassium channel opener.
28 citations
,
August 2013 in “Hypertension” Potassium channel openers help form elastic fibers in arteries and can treat elastin deficiency and hypertension.
18 citations
,
October 2020 in “Journal of Pharmacology and Experimental Therapeutics” KATP channel openers may cause peripheral edema by reducing lymphatic contractions and flow.
3 citations
,
April 2023 in “Frontiers in Pharmacology” ATP-sensitive K+ channel subunits, particularly Sur2A, play a significant role in various cancers.
3 citations
,
March 2012 in “Arab Journal of Urology” Certain drugs can reduce bladder muscle contractions, potentially helping treat bladder diseases.
9 citations
,
June 2017 in “Pharmacological Reports” ATP-sensitive potassium channels play a role in chloroquine-induced itch in mice.
1 citations
,
January 1992 in “Juntendō Igaku/Juntendo igaku” Minoxidil promotes hair growth by increasing blood flow and directly affecting hair follicles.
152 citations
,
April 2012 in “Recent Patents on Inflammation & Allergy Drug Discovery” Minoxidil treats hair loss, promotes growth, has side effects, and has recent patents.
86 citations
,
July 1990 in “British Journal of Pharmacology” Diazoxide, minoxidil sulphate, and cromakalim relax rat blood vessels by opening K+ channels, with some differences in their actions.
42 citations
,
March 2006 in “Drug Discovery Today: Therapeutic Strategies” The conclusion is that we need more effective hair loss treatments than the current ones, and these could include new drugs, gene and stem cell therapy, hormones, and scalp cooling, but they all need thorough safety testing.
7 citations
,
January 2020 in “Journal of Dermatology” Cantu syndrome, which causes excessive hair growth and skin issues, is due to a mutation in the ABCC9 gene, and understanding this could help develop new treatments for hair diseases.
6 citations
,
January 1994 in “PubMed” The molecular mechanisms controlling hair growth phases are not fully understood yet.
1 citations
,
October 2022 in “JAAD case reports” Low-dose oral minoxidil can cause serious heart complications.
December 2025 in “Bolu Abant Izzet Baysal Universitesi Tip Fakultesi Abant Tip Dergisi” Minoxidil did not significantly affect epilepsy in rats.
112 citations
,
October 2005 in “Mayo Clinic Proceedings” Minoxidil and finasteride can slow hair loss and stimulate regrowth, but won't restore all lost hair or reverse complete baldness.